title: Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial.
abstract: One hundred seventy-eight patients were enrolled in a placebo-controlled trial to evaluate three interferon-alpha preparations administered parenterally for the treatment of condyloma acuminatum. When all interferon groups were combined and compared with placebo, interferon recipients had greater rates of complete, 75%, 50%, and 25% lesion resolution than did placebo recipients (P = .21, P = .14, P = .02, and P = .02, respectively). Rates of lesion resolution were higher among women than among men, and women were more likely than men to respond to interferon. Virologic measurements in paired lesion biopsies did not correlate with interferon treatment or disease outcome. Although interferon toxicity was observed frequently, no participant withdrew from the study because of side effects, and dosage alterations were not required. Parenterally administered interferon-alpha is more effective than placebo in treating condyloma acuminatum, although rates of complete response are low. Different regimens, including combination therapy, should be evaluated for treatment of this common sexually transmitted disease.
authors.affiliation: Department of Medicine, University of Rochester, School of Medicine, NY 14642.
authors.forename: R C
authors.initials: RC
authors.lastname: Reichman
authors.forename: D
authors.initials: D
authors.lastname: Oakes
authors.forename: W
authors.initials: W
authors.lastname: Bonnez
authors.forename: D
authors.initials: D
authors.lastname: Brown
authors.forename: H R
authors.initials: HR
authors.lastname: Mattison
authors.forename: A
authors.initials: A
authors.lastname: Bailey-Farchione
authors.forename: M H
authors.initials: MH
authors.lastname: Stoler
authors.forename: L M
authors.initials: LM
authors.lastname: Demeter
authors.forename: S K
authors.initials: SK
authors.lastname: Tyring
authors.forename: L
authors.initials: L
authors.lastname: Miller
mesh_terms: D000328:Adult; D001727:Bisexuality; D003218:Condylomata Acuminata / Q000628:therapy*; D004279:DNA, Viral / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006716:Homosexuality; D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D027383:Papillomaviridae / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D012008:Recurrence; D012044:Regression Analysis; D012737:Sex Factors
chemical_list: D004279:DNA, Viral; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins